SCILEX HOLDING CO (SCLX) Stock Price, Forecast & Analysis
NASDAQ:SCLX • US80880W2052
SCLX Key Statistics, Chart & Performance
The current stock price of SCLX is 8.15 USD. In the past month the price decreased by -5.52%. In the past year, price decreased by -0.61%.
SCLX Technical Analysis
SCLX Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
SCLX Forecast & Estimates
6 analysts have analysed SCLX and the average price target is 499.8 USD. This implies a price increase of 6032.52% is expected in the next year compared to the current price of 8.15.
SCLX Ownership
SCLX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.22 | 994.53B | ||
| JNJ | JOHNSON & JOHNSON | 21.3 | 598.542B | ||
| MRK | MERCK & CO. INC. | 22.41 | 307.324B | ||
| PFE | PFIZER INC | 9.07 | 157.21B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.24 | 126.97B | ||
| ZTS | ZOETIS INC | 18.73 | 57.775B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.12 | 26.674B | ||
| VTRS | VIATRIS INC | 6.18 | 17.196B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.03 | 13.117B | ||
| AXSM | AXSOME THERAPEUTICS INC | 204.53 | 8.262B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SCLX
Company Profile
Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. The company is headquartered in Palo Alto, California and currently employs 30 full-time employees. The company went IPO on 2021-01-11. The Company’s commercial products include ZTlidoO (lidocaine topical system) 1.8% for the relief of neuropathic pain associated with postherpetic neuralgia (PHN); ELYXYB, a ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, it focuses on product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXAO), an epidural injections formulation to treat lumbosacral radicular pain, or sciatica; SP-103 (lidocaine topical system) 5.4%, a ZTlido formulation, for the treatment of acute pain; and SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (SP-104) for fibromyalgia treatment.
Company Info
SCILEX HOLDING CO
960 San Antonio Road
Palo Alto CALIFORNIA US
Employees: 30
Phone: 16505164310
SCILEX HOLDING CO / SCLX FAQ
Can you describe the business of SCILEX HOLDING CO?
Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. The company is headquartered in Palo Alto, California and currently employs 30 full-time employees. The company went IPO on 2021-01-11. The Company’s commercial products include ZTlidoO (lidocaine topical system) 1.8% for the relief of neuropathic pain associated with postherpetic neuralgia (PHN); ELYXYB, a ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, it focuses on product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXAO), an epidural injections formulation to treat lumbosacral radicular pain, or sciatica; SP-103 (lidocaine topical system) 5.4%, a ZTlido formulation, for the treatment of acute pain; and SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (SP-104) for fibromyalgia treatment.
Can you provide the latest stock price for SCILEX HOLDING CO?
The current stock price of SCLX is 8.15 USD. The price decreased by -0.73% in the last trading session.
What is the dividend status of SCILEX HOLDING CO?
SCLX does not pay a dividend.
What is the ChartMill rating of SCILEX HOLDING CO stock?
SCLX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Which stock exchange lists SCLX stock?
SCLX stock is listed on the Nasdaq exchange.
What do analysts say about SCILEX HOLDING CO (SCLX) stock?
6 analysts have analysed SCLX and the average price target is 499.8 USD. This implies a price increase of 6032.52% is expected in the next year compared to the current price of 8.15.
Can you provide the short interest for SCLX stock?
The outstanding short interest for SCILEX HOLDING CO (SCLX) is 2.64% of its float.